Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: J Clin Pharmacol. 2019 Dec 4;60(4):444–452. doi: 10.1002/jcph.1559

Figure 2.

Figure 2.

Proposed neuropathy dose-adjustment algorithm for (A) paclitaxel, (B) nab-paclitaxel, and (C) ixabepilone. Dose reduction or discontinuation scenarios were chosen for the algorithm such that the predicted proportion of patients with a neuropathy score ≥8 on C7D1 is at least 30% fewer compared to no dose reduction. C, cycle; D, day.